1081 Vulvar cancer treatment between 2010 and 2019: the experience of a single Romanian cancer center

Introduction/Background* The purpose of this study was to evaluate 5-year overall survival (OS), disease free survival (DFS) and local control (LC) for patients diagnosed with primary vulvar cancer and treated at Institute of Oncology “Prof.Dr.Ion Chiricuta” Cluj-Napoca, Romania. Methodology Between 2010 and 2019 a number of 306 patients with vulvar cancer were treated in our institution, from which we included in this retrospective study 233 patients with squamous cell vulvar cancer; based on FIGO staging: 19 (8.2%) patients were stage 0, 115 (49.4%) stage I, 17 (7.3%) stage II, 66 (28.3%) stage III and 16 (6.8%) stage IV. 146 patients (62.7%) underwent exclusive surgery, 70 (30%) had surgery combined with adjuvant treatment and 17 (7.3%) with palliative treatment. After these therapeutic modalities patients were followed for a median of 47.1 months (minimum 4.5 months and maximum 122.4 months). Result(s)* The median age was 68 years (minimum of 28 years and maximum of 89 years) and median number of cases per year was 23.3. The OS by stage of disease was 95%, 84%, 72%, 37% respectively 12% for stage 0, I, II, III respectively IV (p Conclusion* Squamous cell vulvar cancer is a rare cancer in our institution. Surgery remains the best treatment modality for early stages of the disease (stage I and II) and gives high survival rate, DFS and LC, among negative lymph nodes involvement and without extracapsular effraction. For better outcomes there is need for treatment personalization according to new international protocols.